[1] Yuan ZH, Wang J, Zhang HR, et al. Glycocholic acid aggravates liver fibrosis by promoting the up-regulation of connective tissue growth factor in hepatocytes. Cell Signal, 2023; 101, 110508. doi:  10.1016/j.cellsig.2022.110508
[2] Hirschfield GM, Dyson JK, Alexander GJM, et al. The British society of gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut, 2018; 67, 1568−94. doi:  10.1136/gutjnl-2017-315259
[3] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol, 2019; 70, 151−71. doi:  10.1016/j.jhep.2018.09.014
[4] Cao XX, Gao YQ, Zhang WH, et al. Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai. Chin J Hepatol, 2015; 23, 569−73. (In Chinese)
[5] Pinheiro D, Dias I, Silva KR, et al. Mechanisms underlying cell therapy in liver fibrosis: an overview. Cells, 2019; 8, 1339. doi:  10.3390/cells8111339
[6] Lee JH, Lee S, Park HJ, et al. Human liver stem cell transplantation alleviates liver fibrosis in a rat model of CCl4-induced liver fibrosis. Int J Stem Cells, 2021; 14, 475−84. doi:  10.15283/ijsc21031
[7] Sun XJ, Guo SL. Effectiveness of cell- and colony stimulating factor-based therapy for liver cirrhosis: a network meta-analysis of randomized controlled trials. Cytotherapy, 2022; 24, 516−25. doi:  10.1016/j.jcyt.2021.11.006
[8] Carvalho AB, Quintanilha LF, Dias JV, et al. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells, 2008; 26, 1307−14. doi:  10.1634/stemcells.2007-0941
[9] Kean TJ, Lin P, Caplan AI, et al. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int, 2013; 2013, 732742.
[10] Yin JQ, Zhu J, Ankrum JA. Manufacturing of primed mesenchymal stromal cells for therapy. Nat Biomed Eng, 2019; 3, 90−104. doi:  10.1038/s41551-018-0325-8
[11] Sang JF, Shi XL, Han B, et al. Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis. Hepatob Pancreat Dis Int, 2016; 15, 602−11. doi:  10.1016/S1499-3872(16)60141-8
[12] Cao HC, Yang JF, Yu J, et al. Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure. BMC Med, 2012; 10, 56. doi:  10.1186/1741-7015-10-56
[13] Zhang EG, Yang Y, Chen SY, et al. Bone marrow mesenchymal stromal cells attenuate silica-induced pulmonary fibrosis potentially by attenuating Wnt/β-catenin signaling in rats. Stem Cell Res Ther, 2018; 9, 311. doi:  10.1186/s13287-018-1045-4
[14] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006; 8, 315−7. doi:  10.1080/14653240600855905
[15] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol, 2017; 14, 397−411. doi:  10.1038/nrgastro.2017.38
[16] Endo S, Nakata K, Ohuchida K, et al. Autophagy is required for activation of pancreatic stellate cells, associated with pancreatic cancer progression and promotes growth of pancreatic tumors in mice. Gastroenterology, 2017; 152, 1492-1506. e24.
[17] Liu RP, Li XJY, Huang ZM, et al. C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. Hepatology, 2018; 67, 1441−57. doi:  10.1002/hep.29540
[18] Mousavi K, Niknahad H, Li HF, et al. The activation of nuclear factor-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling blunts cholestasis-induced liver and kidney injury. Toxicol Res (Camb), 2021; 10, 911−27. doi:  10.1093/toxres/tfab073
[19] Ommati MM, Niknahad H, Najibi A, et al. Cholestasis-associated pulmonary inflammation, oxidative stress, and tissue fibrosis: the protective role of the biogenic amine agmatine. Pharmacology, 2023; 108, 379−393. doi:  10.1159/000530307
[20] Kisseleva T. The origin of fibrogenic myofibroblasts in fibrotic liver. Hepatology, 2017; 65, 1039−43. doi:  10.1002/hep.28948
[21] Siapati EK, Roubelakis MG, Vassilopoulos G. Liver regeneration by hematopoietic stem cells: have we reached the end of the road?. Cells, 2022; 11, 2312. doi:  10.3390/cells11152312
[22] Mishra PJ, Banerjee D. Activation and differentiation of mesenchymal stem cells. Methods Mol Biol, 2017; 1154, 201−9.
[23] Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell, 2011; 19, 257−72. doi:  10.1016/j.ccr.2011.01.020
[24] Duman DG, Zibandeh N, Ugurlu MU, et al. Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model. Mol Biol Rep, 2019; 46, 2997−3008. doi:  10.1007/s11033-019-04736-4
[25] Feng Y, Li YJ, Xu MX, et al. Bone marrow mesenchymal stem cells inhibit hepatic fibrosis via the AABR07028795.2/rno-miR-667-5p axis. Stem Cell Res Ther, 2022; 13, 375. doi:  10.1186/s13287-022-03069-7
[26] Xu YN, Xu W, Zhang X, et al. BM-MSCs overexpressing the Numb enhance the therapeutic effect on cholestatic liver fibrosis by inhibiting the ductular reaction. Stem Cell Res Ther, 2023; 14, 45. doi:  10.1186/s13287-023-03276-w
[27] Sun LH, Fan XT, Zhang LJ, et al. Bone mesenchymal stem cell transplantation via four routes for the treatment of acute liver failure in rats. Int J Mol Med, 2014; 34, 987−96. doi:  10.3892/ijmm.2014.1890
[28] Huang QL, Cheng XM, Luo C, et al. Placental chorionic plate-derived mesenchymal stem cells ameliorate severe acute pancreatitis by regulating macrophage polarization via secreting TSG-6. Stem Cell Res Ther, 2021; 12, 337. doi:  10.1186/s13287-021-02411-9
[29] Yuan MQ, Hu X, Yao LC, et al. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. Stem Cell Res Ther, 2022; 13, 179. doi:  10.1186/s13287-022-02858-4
[30] Lu YB, Zhang W, Tian ZM, et al. The optimal transplantation strategy of umbilical cord mesenchymal stem cells in spinal cord injury: a systematic review and network meta-analysis based on animal studies. Stem Cell Res Ther, 2022; 13, 441.
[31] Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol, 2003; 38, S38-53.
[32] Huang Y, Deng X, Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis. Exp Cell Res, 2017; 352, 420−6. doi:  10.1016/j.yexcr.2017.02.038
[33] Tan YW, Huang Y, Mei R, et al. HucMSC-derived exosomes delivered BECN1 induces ferroptosis of hepatic stellate cells via regulating the xCT/GPX4 axis. Cell Death Dis, 2022; 13, 319. doi:  10.1038/s41419-022-04764-2
[34] Lin Y, Yan MC, Bai ZT, et al. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnol, 2022; 20, 432. doi:  10.1186/s12951-022-01636-x
[35] Liu YW, Dong YT, Wu X, et al. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials. Stem Cell Res Ther, 2022; 13, 204. doi:  10.1186/s13287-022-02882-4